Download PDF
Semin Thromb Hemost 2024; 50(05): 733-738
DOI: 10.1055/s-0044-1779632
Review Article

Tranexamic Acid: An Evergreen Hemostatic Agent

Massimo Franchini
1   Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy
,
Daniele Focosi
2   North-Western Tuscany Blood Bank, Pisa University Hospital, Italy
,
Pier Mannuccio Mannucci
3   Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Tranexamic acid (TXA) is an important antifibrinolytic agent, which inhibits plasminogen activation and fibrinolysis. Several controlled randomized trials have investigated the role of TXA in preventing or decreasing blood loss across different surgical interventions or medical conditions characterized by excessive bleeding, consistently documenting its effectiveness and safety. Although the first clinical use of TXA dates back to more than 60 years ago, TXA remains the focus of intense research. This narrative review summarizes the more recent results and indications on the clinical use of TXA.

Keywords

tranexamic acid - antifibrinolytic agent - bleeding - thrombosis


Publication History

Article published online:
09 February 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339 (04) 245-253
    CrossrefPubMedSearch in Google Scholar
  • 2 Franchini M, Mannucci PM. Adjunct agents for bleeding. Curr Opin Hematol 2014; 21 (06) 503-508
    CrossrefPubMedSearch in Google Scholar
  • 3 Franchini M, Mannucci PM. The never ending success story of tranexamic acid in acquired bleeding. Haematologica 2020; 105 (05) 1201-1205
    CrossrefPubMedSearch in Google Scholar
  • 4 Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356 (22) 2301-2311
    CrossrefPubMedSearch in Google Scholar
  • 5 Schulman S. Pharmacologic tools to reduce bleeding in surgery. Hematology (Am Soc Hematol Educ Program) 2012; 2012: 517-521
    CrossrefPubMedSearch in Google Scholar
  • 6 Cai J, Ribkoff J, Olson S. et al. The many roles of tranexamic acid: an overview of the clinical indications for TXA in medical and surgical patients. Eur J Haematol 2020; 104 (02) 79-87
    CrossrefPubMedSearch in Google Scholar
  • 7 Perel P, Ker K, Morales Uribe CH, Roberts I. Tranexamic acid for reducing mortality in emergency and urgent surgery. Cochrane Database Syst Rev 2013; 2013 (01) CD010245
    PubMedSearch in Google Scholar
  • 8 Franchini M, Muñoz M. Towards the implementation of patient blood management across Europe. Blood Transfus 2017; 15 (04) 292-293
    PubMedSearch in Google Scholar
  • 9 Guerra R, Velati C, Liumbruno GM, Grazzini G. Patient blood management in Italy. Blood Transfus 2016; 14 (01) 1-2
    PubMedSearch in Google Scholar
  • 10 Vaglio S, Gentili S, Marano G. et al. The Italian regulatory guidelines for the implementation of patient blood management. Blood Transfus 2017; 15 (04) 325-328
    PubMedSearch in Google Scholar
  • 11 Franchini M, Liumbruno GM. The key role of tranexamic acid in Patient Blood Management programmes. Blood Transfus 2018; 16 (06) 471-472
    PubMedSearch in Google Scholar
  • 12 Gerstein NS, Brierley JK, Windsor J. et al. Antifibrinolytic agents in cardiac and noncardiac surgery: a comprehensive overview and update. J Cardiothorac Vasc Anesth 2017; 31 (06) 2183-2205
    CrossrefPubMedSearch in Google Scholar
  • 13 Henry DA, Carless PA, Moxey AJ. et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; 3: CD001886
    PubMedSearch in Google Scholar
  • 14 Adler Ma SC, Brindle W, Burton G. et al. Tranexamic acid is associated with less blood transfusion in off-pump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011; 25 (01) 26-35
    CrossrefPubMedSearch in Google Scholar
  • 15 Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 2012; 344: e3054
    CrossrefPubMedSearch in Google Scholar
  • 16 Myles PS, Smith JA, Forbes A. et al; ATACAS Investigators of the ANZCA Clinical Trials Network. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017; 376 (02) 136-148
    CrossrefPubMedSearch in Google Scholar
  • 17 Jiang X, Ma XL, Ma JX. Efficiency and safety of intravenous tranexamic acid in simultaneous bilateral total knee arthroplasty: a systematic review and meta-analysis. Orthop Surg 2016; 8 (03) 285-293
    CrossrefPubMedSearch in Google Scholar
  • 18 Lin ZX, Woolf SK. Safety, efficacy, and cost-effectiveness of tranexamic acid in orthopedic surgery. Orthopedics 2016; 39 (02) 119-130
    CrossrefPubMedSearch in Google Scholar
  • 19 Franchini M, Mengoli C, Marietta M. et al. Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. Blood Transfus 2018; 16 (01) 36-43
    CrossrefPubMedSearch in Google Scholar
  • 20 Sun Y, Jiang C, Li Q. A systematic review and meta-analysis comparing combined intravenous and topical tranexamic acid with intravenous administration alone in THA. PLoS One 2017; 12 (10) e0186174
    CrossrefPubMedSearch in Google Scholar
  • 21 Vaglio S, Prisco D, Biancofiore G. et al. Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus 2016; 14 (01) 23-65
    PubMedSearch in Google Scholar
  • 22 Devereaux PJ, Marcucci M, Painter TW. et al; POISE-3 Investigators. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med 2022; 386 (21) 1986-1997
    CrossrefPubMedSearch in Google Scholar
  • 23 Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS. et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384 (9947) 980-1004
    CrossrefPubMedSearch in Google Scholar
  • 24 Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2015; 6 (06) CD007872
    PubMedSearch in Google Scholar
  • 25 Franchini M, Mengoli C, Cruciani M. et al. Safety and efficacy of tranexamic acid for prevention of obstetric haemorrhage: an updated systematic review and meta-analysis. Blood Transfus 2018; 16 (04) 329-337
    PubMedSearch in Google Scholar
  • 26 Muñoz M, Stensballe J, Ducloy-Bouthors AS. et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus 2019; 17 (02) 112-136
    PubMedSearch in Google Scholar
  • 27 Shakur H, Roberts I, Bautista R. et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376 (9734) 23-32
    CrossrefPubMedSearch in Google Scholar
  • 28 Roberts I, Shakur H, Afolabi A. et al; CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377 (9771) 1096-1101 , 1101.e1–1101.e2
    CrossrefPubMedSearch in Google Scholar
  • 29 World Health Organization. Tranexamic acid. Model list of essential medicines. Accessed January 22, 2023 at: https://list.essentialmeds.org/recommendations/152
    PubMed
  • 30 Gruen RL, Mitra B, Bernard SA. et al; PATCH-Trauma Investigators and the ANZICS Clinical Trials Group. Prehospital tranexamic acid for severe trauma. N Engl J Med 2023; 389 (02) 127-136
    CrossrefPubMedSearch in Google Scholar
  • 31 CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet 2019; 394 (10210): 1713-1723
    CrossrefPubMedSearch in Google Scholar
  • 32 Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2015; 2015 (05) CD004896
    PubMedSearch in Google Scholar
  • 33 WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet 2017; 389 (10084): 2105-2116
    CrossrefPubMedSearch in Google Scholar
  • 34 World Health Organization. WHO Recommendation on Tranexamic Acid for the Treatment of Postpartum Haemorrhage. Geneva: WHO; 2017
    Search in Google Scholar
  • 35 Shakur H, Beaumont D, Pavord S, Gayet-Ageron A, Ker K, Mousa HA. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev 2018; 2 (02) CD012964
    PubMedSearch in Google Scholar
  • 36 WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage – Highlights and Key Messages. Accessed on October 5, 2023 at: https://www.who.int/publications/i/item/WHO-RHR-17.21
    PubMed
  • 37 Bennett C, Klingenberg SL, Langholz E, Gluud LL. Tranexamic acid for upper gastrointestinal bleeding. Cochrane Database Syst Rev 2014; 2014 (11) CD006640
    PubMedSearch in Google Scholar
  • 38 HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020; 395 (10241): 1927-1936
    CrossrefPubMedSearch in Google Scholar
  • 39 Lee PL, Yang KS, Tsai HW, Hou SK, Kang YN, Chang CC. Tranexamic acid for gastrointestinal bleeding: a systematic review with meta-analysis of randomized clinical trials. Am J Emerg Med 2021; 45: 269-279
    CrossrefPubMedSearch in Google Scholar
  • 40 Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Antifibrinolytic Trials Collaboration. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; 391 (10116): 125-132
    CrossrefPubMedSearch in Google Scholar
  • 41 Germans MR, Dronkers WJ, Baharoglu MI. et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2022; 11 (11) CD001245
    PubMedSearch in Google Scholar
  • 42 Franchini M, Rossetti G, Tagliaferri A. et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11 (05) 504-509
    CrossrefPubMedSearch in Google Scholar
  • 43 Rocino A, Coppola A, Franchini M. et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014; 12 (04) 575-598
    PubMedSearch in Google Scholar
  • 44 Srivastava A, Santagostino E, Dougall A. et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (06) 1-158
    CrossrefPubMedSearch in Google Scholar
  • 45 van Galen KPM, Engelen ET, Mauser-Bunschoten EP, van Es RJJ, Schutgens REG. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2019; 4 (04) CD011385
    PubMedSearch in Google Scholar
  • 46 Coppola A, Windyga J, Tufano A, Yeung C, Di Minno MND. Treatment for preventing bleeding in people with haemophilia or other congenital bleeding disorders undergoing surgery. Cochrane Database Syst Rev 2015; 2 (02) CD009961
    PubMedSearch in Google Scholar
  • 47 Ragni MV, Rothenberger SD, Feldman R. et al. Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. Lancet Haematol 2023; 10 (08) e612-e623
    CrossrefPubMedSearch in Google Scholar
  • 48 Tran HT, Sørensen B, Rea CJ. et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2014; 20 (03) 369-375
    CrossrefPubMedSearch in Google Scholar
  • 49 Holmström M, Tran HT, Holme PA. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two-centre experience. Haemophilia 2012; 18 (04) 544-549
    CrossrefPubMedSearch in Google Scholar
  • 50 Windyga J, Stefanska-Windyga E, Odnoczko E, Baran B, Czubak G. Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors. Haemophilia 2016; 22 (05) e465-e468
    CrossrefPubMedSearch in Google Scholar
  • 51 Valentino LA, Holme PA. Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?. Haemophilia 2015; 21 (06) 709-714
    CrossrefPubMedSearch in Google Scholar
  • 52 Pasca S, Ambaglio C, Rocino A, Santoro C, Cantori I, Zanon E. FAIR Study Group. Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry. J Thromb Thrombolysis 2019; 47 (01) 129-133
    CrossrefPubMedSearch in Google Scholar
  • 53 Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004; 351 (07) 683-694
    CrossrefPubMedSearch in Google Scholar
  • 54 Leebeek FWG, Eikenboom JCJ. Von Willebrand's disease. N Engl J Med 2017; 376 (07) 701-702
    CrossrefPubMedSearch in Google Scholar
  • 55 Levi M, de Boer JP, Roem D, ten Cate JW, Hack CE. Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay. Thromb Haemost 1992; 67 (01) 111-116
    Thieme ConnectPubMedSearch in Google Scholar
  • 56 Federici AB, Castaman G, Iorio A, Oliovecchio E. ; on behalf of Investigators of ProDesWil Study. Safety and effectiveness of desmopressin for the management of delivery and major surgery in patients with mild-moderate von willebrand disease: final interim analysis of the ProDesWil study. Paper presented at: Oral Communication at the 57th Annual Meeting and Exposition of the American Society of Hematology, abstract 759, 2015
    PubMedSearch in Google Scholar
  • 57 Federazione Centri per la Diagnosi della Trombosi e la Sorveglianza delle Terapie Antitrombotiche (FCSA). Guida alla Terapia Antitrombotica ( 2022. Ed.).
    Search in Google Scholar
  • 58 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326S-e350S
    CrossrefPubMedSearch in Google Scholar
  • 59 Engelen ET, Schutgens RE, Mauser-Bunschoten EP, van Es RJ, van Galen KP. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018; 7 (07) CD012293
    PubMedSearch in Google Scholar